TY  - CHAP
M1  - Book, Section
TI  - Renal Cell Carcinoma
A1  - Michaelson, M. Dror
A2  - Chabner, Bruce A.
A2  - Longo, Dan L.
PY  - 2016
T2  - Harrison's Manual of Oncology, 2e
AB  - The  incidence  of  renal  cell  carcinoma  (RCC)  in  the  United  States  has  been  rising  steadily,  with  an  estimated  65,150  cases  and  13,680  deaths  in  2013  (1).  RCC  is  the  6th  most  common  malignancy  in  men  and  the  8th  in  women  with  a  male-to-female  ratio  of  1.6:1.  The  majority  of  patients  are  now  identified  through  incidental  findings  on  imaging  studies.  Fortunately,  the  prognosis  of  early  stage  disease  is  excellent.  However,  25%  of  patients  have  advanced  disease  at  initial  presentation,  and  metastatic  disease  is  generally  considered  incurable.  The  median  survival  for  patients  with  metastatic  disease  historically  was  12–15  months,  with  5-year  survival  of  10%  (2).  However,  this  appears  to  have  changed  over  the  past  decade,  as  advances  in  the  understanding  of  RCC  biology  combined  with  the  development  of  novel  targeted  therapies  have  improved  and  redefined  management  of  advanced  RCC.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - hemonc.mhmedical.com/content.aspx?aid=1127648527
ER  -